ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2847

Survivin Co-Ordinates Formation of Follicular T-Cells in Rheumatoid Arthritis

Maria Bokarewa1, Karin Andersson2, Malin Erlandsson2, Mattias Svensson2, Nicola Cavallini3 and Mikael Brisslert2, 1Guldhedsgatan 10, University of Goteborg, Goteborg, Sweden, 2Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, 3Rheumatology and Inflammation Research, University of Göteborg, Göteborg, Sweden

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: autoantibodies and rheumatoid arthritis, pathogenesis, T cells

  • Tweet
  • Email
  • Print
Session Information

Title: T cell Biology and Targets in Autoimmune Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose

Survivin is a proto-oncogene that regulates cell division and apoptosis. Recently, survivin has emerged as a biomarker of persistently active and joint destructive rheumatoid arthritis (RA). High serum levels of survivin are frequently associated with antibodies against cyclic citrullinated epitopes (ACPA).

Here we study the role of survivin in the formation of follicular T-cells and in the antibody production in RA.

Methods

The intracellular expression of survivin and Bcl-6 was studied in RA patients (age 21-71 years, disease duration 1-49 years) by flow cytometry and qPCR. DNA binding of survivin and Bcl-6 was studied in stimulated PBMC by chromatin immunoprecipitation.

The effect of survivin modulation on the follicular T-cells and on production of antigen-specific and autoantibodies was studied in collagen-immunized arthritis (CIA) mice, where Survivin transcription was inhibited by shRNA–lentiviral construct (shSurv, 106-107 particles/mouse). In separate experiments, CIA mice were vaccinated with survivin-peptides before the CII immunization. Control CIA mice received non-targeting transduction particles or were vaccinated with irrelevant peptides. 

Results

The sSurv+RA group (n=76) was characterized by higher frequency of RF+ and ACPA+ patients, as well as by higher levels of ACPA compared to sSurv-RA (n=68). Intracellular survivin was present in the effector (CD45RA+CD27-) CD4+ T cells. Survivin co-expressed with Bcl-6 on lymphocytes of arthritic mice and in RA patients. Bcl-6+ subset comprised 7-38% of surv+CD4+ T-cells and was also CXCR5+. Bcl6+Surv+ subset of CD4 T cells and mRNA levels of Bcl-6 were lower in blood of sSurv+patients.

Follicular (CXCR5+PD-1+) CD4 population in spleen and lymph nodes of arthritic DBA1 mice were mostly surv+Bcl6+. Mice vaccinated with survivin-derived peptides developed the phenotype similar to sSurv+RA patients and had high serum levels of survivin and higher levels of aCII and RF antibodies. Surv-vaccinated mice had significantly increased survivin expression and the subset of surv+Bcl-6+ within CXCR5+CD4+ cells in LN. shSurv-treated mice had reduced CD4+surv+ and CD19+surv+ populations in spleens, and smaller CXCR5+CD4+ and CXCR5+B220+ populations, while Bcl-6 gene transcription was increased. Inhibiting survivin led to lower levels of anti-CII antibodies and lower RF, suggesting insufficient Bcl-6 and poor Tfh development. Chromatin immunoprecipitation showed that survivin binds within Bcl-6 responsive element of Blipm-1 promoter potentially controlling transcriptional activity of Bcl-6. 

Conclusion

In this study we demonstrate that RA patients have co-expression of survivin and Bcl-6 in the follicular T helper cells. Changes in survivin transcription modulate formation and function of the follicular T cells by regulating transcriptional activity of Bcl-6, essential factor of germinal center formation and autoantibody production.


Disclosure:

M. Bokarewa,
None;

K. Andersson,
None;

M. Erlandsson,
None;

M. Svensson,
None;

N. Cavallini,
None;

M. Brisslert,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/survivin-co-ordinates-formation-of-follicular-t-cells-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology